Literature DB >> 3876836

Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis.

G Moxley, S Ruddy.   

Abstract

Because cleavage products of the third component of complement augment inflammation and may contribute to arthritis, we used a competitive inhibition radioimmunoassay to measure levels of the low molecular weight cleavage products of the third component of complement, C3a and C3adesArg, in 72 synovial fluid samples. Mean levels of C3a/C3adesArg were more than sevenfold higher in 41 patients who had rheumatoid arthritis than in 15 patients who had degenerative joint disease or 5 patients who had traumatic arthritis. Striking elevations were also present in 2 patients who had acute gouty arthritis. A calculation of the fraction of intraarticular C3 cleaved showed that the patients with rheumatoid arthritis had a mean C3 cleavage of 11.6 +/- 11.0%, which was significantly higher than values of less than 1.5% for patients with degenerative joint disease or traumatic arthritis. In rheumatoid arthritis and gouty arthritis, specific immunoassay identified substantial quantities of the initial C3 cleavage fragments.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876836     DOI: 10.1002/art.1780281003

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

1.  Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q.

Authors:  Leonie M Vogt; Ewa Kwasniewicz; Simone Talens; Carsten Scavenius; Ewa Bielecka; Kristina N Ekdahl; Jan J Enghild; Matthias Mörgelin; Tore Saxne; Jan Potempa; Anna M Blom
Journal:  J Immunol       Date:  2020-04-06       Impact factor: 5.422

2.  Normal pregnancy is characterized by systemic activation of the complement system.

Authors:  Karina Richani; Eleazar Soto; Roberto Romero; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Jyh Kae Nien; Samuel Edwin; Yeon Mee Kim; Joon-Seok Hong; Moshe Mazor
Journal:  J Matern Fetal Neonatal Med       Date:  2005-04

3.  Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.

Authors:  A Familian; A E Voskuyl; G J van Mierlo; H A Heijst; J W R Twisk; B A C Dijkmans; C E Hack
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

4.  Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase.

Authors:  P J Jose; I K Moss; R N Maini; T J Williams
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

5.  Comparison of phenotype expression by mononuclear phagocytes within subcutaneous gouty tophi and rheumatoid nodules.

Authors:  D G Palmer; N Hogg; I Denholm; C A Allen; J Highton; P A Hessian
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

6.  Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells.

Authors:  Carolyn M Summers; Andrea L Hammons; Jasbir Arora; Suhong Zhang; Jeanine Jochems; Ian A Blair; Alexander S Whitehead
Journal:  Eur J Pharmacol       Date:  2014-03-18       Impact factor: 4.432

7.  Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium.

Authors:  P Gulati; D Guc; C Lemercier; D Lappin; K Whaley
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

8.  IgE rheumatoid factors: quantification in synovial fluid and ability to induce synovial mast cell histamine release.

Authors:  B Gruber; D Ballan; P D Gorevic
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

9.  Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy.

Authors:  M Doherty; N Richards; J Hornby; R Powell
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

10.  Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation.

Authors:  Andreas P Sjöberg; Gavin A Manderson; Matthias Mörgelin; Anthony J Day; Dick Heinegård; Anna M Blom
Journal:  Mol Immunol       Date:  2008-10-29       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.